Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Emilie Hafliger"'
Autor:
Romain Varnier, Thibaut Garrivier, Emilie Hafliger, Aymeric Favre, Clélia Coutzac, Clément Spire, Pauline Rochefort, Matthieu Sarabi, Françoise Desseigne, Pierre Guibert, Anne Cattey-Javouhey, Pamela Funk-Debleds, Charles Mastier, Adrien Buisson, David Pérol, Oliver Trédan, Jean-Yves Blay, Jean-Marc Phelip, Christelle de la Fouchardiere
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Immune checkpoint inhibitors (ICI) have been developed in gastric adenocarcinomas and approved in first-line metastatic setting (in combination with chemotherapy) as well as in pretreated patients. Microsatellite instability-high (MSI-H) tumors are p
Externí odkaz:
https://doaj.org/article/2224c227c53b4b719b18694921a201c0
Autor:
Emilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, Audrey Perret, Claire Gallois, Maria Antista, Lorenzo Pilla, Thierry Lecomte, Mario Scartozzi, Emilie Soularue, Lisa Salvatore, Vincent Bourgeois, Massimiliano Salati, David Tougeron, Ludovic Evesque, Jean-Nicolas Vaillant, Reem El-Khoury, Sara Lonardi, Chiara Cremolini, Julien Taieb
Publikováno v:
European journal of cancer (Oxford, England : 1990). 168
Encorafenib plus cetuximab is efficient in anti-EGFR-naïve patients with BRAFWe retrospectively collected a series of patients with BRAFm mCRC treated with B + E after previous anti-EGFR treatment, in 14 centers. Progression-free survival (PFS) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::242541ca117fdb08d81cbfd366e1877b
https://pubmed.ncbi.nlm.nih.gov/35436675
https://pubmed.ncbi.nlm.nih.gov/35436675
Autor:
Christophe Locher, Emilie Hafliger, Anna Pellat, Roger Faroux, Claire Gallois, Julien Taieb, Edouard Auclin, A. Perret, Vincent Hautefeuille, Violaine Randrian, Anthony Turpin, Simon Pernot, Lola-Jade Palmieri, Olivier Dubreuil, Debora Basile, Clélia Coutzac, Marie Dior, Pascal Artru
Publikováno v:
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 54(5)
Background In case of contraindication or intolerance to fluoropyrimidines, raltitrexed is a validated alternative in metastatic colorectal cancer (mCRC), associated or not with oxaliplatin. Little is known about the outcomes of raltitrexed combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc3c2e7928e17ccc0dde94acf092193
https://pubmed.ncbi.nlm.nih.gov/34470724
https://pubmed.ncbi.nlm.nih.gov/34470724